A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors.
In: Hepatitis Weekly, 2023-01-30, S. 19-19
serialPeriodical
Zugriff:
The article discusses a study which examined the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate as treatment for pancreatic neuroendocrine tumors. Topics covered include the incidence of adverse events (AE), the distribution of overall survival (OS), and the duration of response.
Titel: |
A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors.
|
---|---|
Zeitschrift: | Hepatitis Weekly, 2023-01-30, S. 19-19 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1086-0223 (print) |
Sonstiges: |
|